These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 17175893)

  • 1. Monitoring cardiac function by B-type natriuretic peptide (BNP) in patients with infantile Pompe's disease treated with recombinant alpha-glucosidase.
    Hahn A; Schmidt D; Hagel KJ; Neubauer BA; Katz N
    Clin Lab; 2006; 52(11-12):615-9. PubMed ID: 17175893
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Morphological changes in muscle tissue of patients with infantile Pompe's disease receiving enzyme replacement therapy.
    Winkel LP; Kamphoven JH; van den Hout HJ; Severijnen LA; van Doorn PA; Reuser AJ; van der Ploeg AT
    Muscle Nerve; 2003 Jun; 27(6):743-51. PubMed ID: 12766987
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Enzyme replacement therapy in late-onset Pompe's disease: a three-year follow-up.
    Winkel LP; Van den Hout JM; Kamphoven JH; Disseldorp JA; Remmerswaal M; Arts WF; Loonen MC; Vulto AG; Van Doorn PA; De Jong G; Hop W; Smit GP; Shapira SK; Boer MA; van Diggelen OP; Reuser AJ; Van der Ploeg AT
    Ann Neurol; 2004 Apr; 55(4):495-502. PubMed ID: 15048888
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Enzyme replacement therapy in Pompe's disease].
    Merk T; Wibmer T; Schumann C; Krüger S
    Med Klin (Munich); 2007 Jul; 102(7):570-3. PubMed ID: 17634875
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Pompe's disease: the role for early diagnosis and treatment].
    Cerini E; Bini M; Donati A; Andaloro L; Compagnoni G
    Pediatr Med Chir; 2007; 29(5):270-2. PubMed ID: 18402397
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safety and efficacy of recombinant acid alpha-glucosidase (rhGAA) in patients with classical infantile Pompe disease: results of a phase II clinical trial.
    Klinge L; Straub V; Neudorf U; Schaper J; Bosbach T; Görlinger K; Wallot M; Richards S; Voit T
    Neuromuscul Disord; 2005 Jan; 15(1):24-31. PubMed ID: 15639117
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Pompe's disease. Part II. Treatment strategies and enzyme replacement].
    Illés Z; Várdi Visy K
    Ideggyogy Sz; 2009 Sep; 62(9-10):299-307. PubMed ID: 19835271
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [A retrospective study of six patients with late-onset Pompe disease].
    Saux A; Laforet P; Pagès AM; Figarella-Branger D; Pellissier JF; Pagès M; Labauge P
    Rev Neurol (Paris); 2008 Apr; 164(4):336-42. PubMed ID: 18439925
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Three hypotonic neonates with hypertrophic cardiomyopathy: Pompe's disease].
    Willemsen MA; Jira PE; Gabreëls FJ; van der Ploeg AT; Smeitink JA
    Ned Tijdschr Geneeskd; 1998 Jun; 142(24):1388-92. PubMed ID: 9752027
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Reversal of cardiac dysfunction after enzyme replacement in patients with infantile-onset Pompe disease.
    Chen LR; Chen CA; Chiu SN; Chien YH; Lee NC; Lin MT; Hwu WL; Wang JK; Wu MH
    J Pediatr; 2009 Aug; 155(2):271-5.e2. PubMed ID: 19486996
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Enzyme replacement therapy in classical infantile pompe disease: results of a ten-month follow-up study.
    Klinge L; Straub V; Neudorf U; Voit T
    Neuropediatrics; 2005 Feb; 36(1):6-11. PubMed ID: 15776317
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pompe's disease.
    van der Ploeg AT; Reuser AJ
    Lancet; 2008 Oct; 372(9646):1342-53. PubMed ID: 18929906
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Glucose tetrasaccharide as a biomarker for monitoring the therapeutic response to enzyme replacement therapy for Pompe disease.
    An Y; Young SP; Kishnani PS; Millington DS; Amalfitano A; Corz D; Chen YT
    Mol Genet Metab; 2005 Aug; 85(4):247-54. PubMed ID: 15886040
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Treatment of Pompe's disease with recombinant enzymes].
    Van Hove JL
    Verh K Acad Geneeskd Belg; 1998; 60(4):347-57. PubMed ID: 9883081
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Anaesthetic management of infants with glycogen storage disease type II: a physiological approach.
    Ing RJ; Cook DR; Bengur RA; Williams EA; Eck J; Dear Gde L; Ross AK; Kern FH; Kishnani PS
    Paediatr Anaesth; 2004 Jun; 14(6):514-9. PubMed ID: 15153218
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Late-onset Pompe's disease.
    Teener JW
    Semin Neurol; 2012 Nov; 32(5):506-11. PubMed ID: 23677658
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Does circulating BNP normalize after heart transplantation in patients with normal hemodynamic and right and left heart functions?
    Talha S; Di Marco P; Doutreleau S; Rouyer O; Piquard F; Geny B
    Clin Transplant; 2008; 22(5):542-8. PubMed ID: 18394002
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Pompe's disease. Part I: pathogenesis and clinical features].
    Illés Z; Trauninger A
    Ideggyogy Sz; 2009 Jul; 62(7-8):231-43. PubMed ID: 19685701
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evidence for functional heterogeneity of circulating B-type natriuretic peptide.
    Liang F; O'Rear J; Schellenberger U; Tai L; Lasecki M; Schreiner GF; Apple FS; Maisel AS; Pollitt NS; Protter AA
    J Am Coll Cardiol; 2007 Mar; 49(10):1071-8. PubMed ID: 17349887
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Alternate circulating pro-B-type natriuretic peptide and B-type natriuretic peptide forms in the general population.
    Lam CS; Burnett JC; Costello-Boerrigter L; Rodeheffer RJ; Redfield MM
    J Am Coll Cardiol; 2007 Mar; 49(11):1193-202. PubMed ID: 17367664
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.